BSG Polyp Surveillance guidelines (originally published in 2002). We chose different time periods to study including 2002, 2005–2006, 2009 (50 patients each) and 2011 (100 patients). We had previously conducted an audit in 2010 (unpublished) and following this embarked on a programme of endoscopist education to improve compliance data.

**Results** Compliance with the BSG Polyp Surveillance guidelines was 33% in 2002, 65% in 2005/2006, 57% in 2009 and 98% in 2011. Based on our unit’s activity 3852 colonoscopies were performed in 2011 with an overall polyp detection rate of 34.6% (1532.9 colonoscopies). 98% compliance with BSG guidelines would have resulted in inappropriate advice being given in 26.5 of those colonoscopies. For every 1% reduction in compliance against the BSG standard (and for our unit based on 2011 figures) an additional 123.5 polyp positive colonoscopies would receive inappropriate guidance on polyp follow-up. In our experience (unpublished), inappropriate advice results in an increase in frequency of follow-up colonoscopies. In our experience (unpublished), inappropriate polyp positive colonoscopies would receive inappropriate guidance on polyp follow-up. In our experience (unpublished), inappropriate guidance results in an increase in frequency of follow-up colonoscopies.

To embark on a programme of endoscopist education to improve compliance data.

**Conclusion** We demonstrate a big improvement in compliance with the BSG guidelines at our unit following a period of investigation. Of the technical misses, 10 (1.7%) were radiological (0.7%, 0.7% and 0.3% for BE, CTACE and CTC respectively) and 8 (1.4%) were endoscopic (0.5% and 0.9% for flexible sigmoidoscopy and colonoscopy). 45% of missed cancers were left-sided and below the splenic flexure.

**Conclusion** This study has shown a lower miss rate in our institution than previously reported, and when compared with other studies.

**Competing interests** None declared.

**REFERENCES**


**PWE-089** THE ROLES OF CYP2C40 AND CYP2C55 IN PREVENTING COLON CANCER
doi:10.1136/gutjnl-2012-302514d.89

**Introduction** Certain Cytochrome P450 (CYP)-dependent arachidonic acid (AA) metabolites are thought to induce therapeutic effects in the colon via activation of peroxisome proliferator activated receptors (PPARs), specifically the PPAR α subtype. The activation of PPAR α leads to changes in the expression and activity of target genes and other transcription factors such as COX-2, NF-kB and AP-1, resulting in anti-inflammatory and anti-tumorigenic effects. CYP2C40 and CYP2C55 are two recently discovered CYPs, isolated from the murine intestinal tract. Their metabolites include 16-HETE, 8,9-EET and 14,15-EET which have been shown to have anti-inflammatory effects both in vitro and in vivo. Evidence suggests that CYP2C40 and CYP2C55 may have a potential therapeutic role to play in colon tumorigenesis. This study aims to determine whether PPAR activation leads to an up-regulation in the expression of CYP2C40 and CYP2C55.

**Methods** CYP2C40 and CYP2C55 promoter regions were isolated from murine DNA via PCR and inserted into a luciferase plasmid (pGL4.10). Plasmid DNA was cloned following transfection into highly competent cells and purified via Midi-Prep recovery. Purified plasmids were transfected into COS-7 and HCA-7 cells and the cells were treated with PPAR α, β and γ ligands Wy14643, GW0742 and Rosiglitazone (COS-7 cells had PPAR α/β/γ over-expressed). Cells were harvested after 24 h incubation and luciferase activity (equivalent to gene expression) was measured in relative light units (RLU) using a reporter assay system.

**Results** In COS-7 cells PPAR α, β and γ ligands led to a significant increase in CYP2C40 RLU from a baseline measurement of (mean ±S.D) 235 (20) to 726 (45), 458 (61) and 466 (42) for PPAR α, β and γ respectively. CYP2C55 showed a significant increase from 154 (6) to 263 (10) and 354 (21) for PPAR α and β respectively (p=0.001). HCA-7 cells were shown to only express endogenous PPAR α and following incubation with PPAR α, β and γ ligands a significant RLU increase was observed in CYP2C40 from 55 (13) to 126 (17) and in CYP2C55 from 62 (11) to 111 (4) for PPAR α (p=0.001).

**Conclusion** The results suggest that a functional peroxisome proliferator response element (PPRE) exists within the promoter regions of CYP2C40 and CYP2C55 and that activation of PPAR α within the HCA-7 cell line leads to a significant increase in CYP2C40 and CYP2C55 expression. Given the beneficial properties of PPAR α and CYP derived AA metabolites it seems that CYP2C40 and CYP2C55 may become important future therapeutic targets in colon cancer.

**Competing interests** None declared.